58³Ô¹Ï

In April 2026, Biocon Limited received approval from Health Canada for its denosumab biosimilars Bosaya and Vevzuo, biosimilars to Prolia and Xgeva, strengthening its global biosimilars portfolio and expanding access to affordable treatments for osteoporosis and cancer-related bone conditions.

In April 2026, Biocon Limited announced the U.S. commercial launch of its denosumab biosimilars Bosaya and Aukelso, expanding its biosimilars portfolio and improving access to affordable treatments for osteoporosis and cancer-related bone conditions.

In February 2026, Biocon Limited received U.S. FDA approval for its weight management drug Liraglutide injection (gSaxenda), strengthening its presence in the global GLP-1 segment and expanding access to affordable treatment for chronic weight management.

In January 2026, Biocon Biologics, a subsidiary of Biocon Limited, expanded its biosimilar oncology portfolio and outlined its strategic vision at the J.P. Morgan Healthcare Conference, strengthening its global position in affordable cancer therapies.

In December 2025, Biocon Limited announced the launch of its GLP-1 peptide, liraglutide, in the Netherlands following approval from the Medicines Evaluation Board (MEB). The drug-device combination, indicated for diabetes and chronic weight management, is being commercialized under the brand names Diavorin and Vobexoryn, marking the company’s first direct branded launch of liraglutide in the European Union.

In October 2025, Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, announced that Health Canada granted a Notice of Compliance (NOC) for Yesintek and Yesintek I.V. (ustekinumab), biosimilars to Stelara (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.

In October 2025, Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, secured a U.S. market entry for Bosaya and Aukelso (denosumab-kyqq), biosimilars to Prolia and Xgeva, respectively, following a settlement and licensing agreement.

In September 2025, Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, received U.S. Food and Drug Administration (FDA) approval for Bosaya and Aukelso (denosumab-kyqq), biosimilars to Prolia and Xgeva, respectively, for all approved indications, with provisional interchangeability designation.

In September 2025, Biocon Limited inaugurated its first U.S. manufacturing facility in Cranbury, New Jersey, through its wholly owned subsidiary Biocon Generics Inc., marking a key milestone in its global expansion and strengthening its supply chain capabilities.

In July 2025, Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, received U.S. Food and Drug Administration (FDA) approval for Kirsty (insulin aspart-xjhz), the first and only interchangeable biosimilar to NovoLog (insulin aspart), indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.

In July 2025, Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, received European Commission (EC) marketing authorisation for Vevzuo and Evfraxy (denosumab), biosimilars to Prolia and Xgeva, respectively, for use across the European Union.

In June 2025, Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, received Health Canada approval (Notice of Compliance) for Yesafili (aflibercept), a biosimilar to Eylea (aflibercept), becoming the first aflibercept biosimilar approved in Canada.

In June 2025, Biocon Limited received approval from the Drugs Controller General of India (DCGI), CDSCO, for its liraglutide drug substance and drug product (6 mg/ml solution for injection in pre-filled pen and cartridge), a generic version of Victoza, indicated for the treatment of Type 2 diabetes mellitus.

In April 2025, Biocon received U.S. Food and Drug Administration (FDA) approval for Jobevne (bevacizumab-nwgd), a biosimilar to Avastin (bevacizumab), for intravenous use in the treatment of multiple types of cancer, expanding its oncology portfolio.

In March 2025, Biocon Ltd received U.S. Food and Drug Administration (FDA) approvals for Lenalidomide capsules and Dasatinib tablets, indicated for the treatment of multiple hematologic conditions including multiple myeloma and chronic myeloid leukemia.

In February 2025, Biocon Limited launched its GLP-1 peptide, liraglutide, in the United Kingdom, following approval from the Medicines and Healthcare products Regulatory Agency (MHRA), with the drug-device combination marketed under the brand names Liraglutide Biocon (gVictoza) for diabetes and Biolide (gSaxenda) for chronic weight management.

In February 2025, Biocon launched Yesintek (ustekinumab-kfce), a biosimilar to Stelara (ustekinumab), in the United States, marking one of the first biosimilar entries for the reference product in the market.

In August 2024, Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, secured market entry for Bmab 1200, a proposed biosimilar to Stelara (ustekinumab), in Europe, the United Kingdom, Canada, and Japan, following a settlement and licensing agreement that resolved patent disputes, with regulatory filings under review.

In May 2024, Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd announced FDA approval for its first-to-file application for Yesafili (aflibercept-jbvf), an interchangeable biosimilar of aflibercept.

In March 2024, Biocon Limited, a global biopharmaceuticals innovator, has obtained MHRA approval in the UK for its complex formulation of Liraglutide (6mg/ml solution for injection in pre-filled pen)

In February 2024, Biocon Limited announces that the Company has signed a settlement and license agreement with Janssen Biotech Inc., and Johnson & Johnson (collectively known as Janssen) that clears the way to commercialize its Bmab 1200, a proposed biosimilar to Stelara, in the United States of America.

In December 2023, Bicara Therapeutics, an associate of Biocon in the US, raised US$ 165 million co-led by Braidwell and TPG.

In September 2023, Biocon Limited announces the acquisition of a manufacturing facility of Eywa Pharma Inc.

In August 2023, Biocon Foundation and Shakti Sustainable Energy Foundation organize Cities and Climate Action Workshop.

In July 2023, Biocon Biologics Ltd (BBL) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of YESAFILI, an aflibercept biosimilar.

In April 2023, Serum Institute of Life Sciences announced to double up its investment in Biocon's unit to US$ 300 million. With this, Biocon's unit will also get access to SILS' 100 million vaccine doses annually.

In February 2023, Biocon raises US$ 129 million from Kotak Mahindra Group asset management to fund biosimilars deal.

In January 2023, Biocon Foundation won the prestigious ‘IHW Gold Award for Diseases Screening Initiative of the Year’ for 2022.

In December 2022, Biocon Limited initiated clinical study of Itolizumab for Ulcerative Colitis in India.

In November 2022, Biocon Biologics completed the acquisition of Viatris’ Global Biosimilars business.

In October 2o22, Biocon ranked at number 8 in the ‘Global Top Employers’ list by the U.S. Science Magazine.

In October 2022, Biocon Foundation, the CSR arm of the Bengaluru-headquartered Biocon Limited, was awarded the ‘Mahatma Award 2022 For Excellence in Social Good’.

In May 2022, Biocon Biologics and Viatris Inc launched a biosimilar product Abevmy (bBevacizumab) in Canada for use in the treatment of cancer.

In February 2022, Biocon got USFDA approval for its Posaconazole Delayed-Release tablets.

Biocon Biologics received Rs. 555 crore (US$ 75 million) capital from ADQ, an Abu Dhabi based primary equity investment.

To expand its generic formulations portfolio, Biocon launched Everolimus tablets in the US.

Biocon Biologics Limited (BBL) and Serum Institute Life Sciences Private Limited (SILS) announced a strategic alliance to develop antibodies for infectious diseases like dengue, HIV, and others.

Biocon Biologics received US$ 150 million capital injection from Goldman Sachs

Semglee (insulin glargine injection) launched in the US

Tata Capital acquired minority stake in Biocon Biologics

True North makes a primary equity investment in Biocon Biologics

Bicara Therapeutics incorporated to advance novel immuno-oncology assets

Ogivri, biosimilar Trastuzumab commercialised in the United States

Biosimilars business consolidated under independent entity Biocon Biologics

Fulphila and Ogivri, jointly developed by Biocon and Mylan, was granted marketing authorisation by the European Commission

Biocon, Sandoz entered global partnership for the next generation biosimilars

Biocon and Mylan’s biosimilar Insulin Glargine, Semglee, received European approval for commercialisation

Fulphila, jointly developed by Biocon and Mylan, approved and launched in the United States.

Biocon launched its biosimilar Bevacizumab in India

Biocon’s first overseas facility in Malaysia started operations

Biocon and Mylan becomes received US Food and Drug Administration (FDA) approval for biosimilar, Trastuzumab

Japan's health regulator approved the sale of its biosimilar, Insulin Glargine, in partnership with FUJIFILM Toyama Chemical

Biocon’s new insulin devices facility inaugurated in Bangalore

Biocon’s research services subsidiary, Syngene, debuted on the Indian stock market

Biocon and Pfizer entered into a strategic global agreement

Syngene inaugurated a fully dedicated research and development facility for Bristol-Myers Squibb at Biocon Park

Biocon launched Insulin Glargine under the brand name Basalog

Biocon, Mylan entered into strategic global partnership to develop biosimilars

Biocon acquired stake in AxiCorp GmbH, a German pharmaceutical company

Biocon divested its legacy enzymes business to Novozymes for US$ 115million to increase focus on developing, manufacturing biopharmaceuticals

India's largest multiproduct Biologics facility was inaugurated

Biocon Park, India’s first private Biotechnology SEZ, was inaugurated

Biocon IPO was launched

Pichia-based rh-Insulin was developed and commercialised in India

Biocon Biopharmaceuticals was established as a JV with CIMAB, Cuba

Biocon become an independent entity

Unilever acquired 50% stake in Biochemizyme and created Biocon Quest India Ltd (BQIL), with Biocon and Unilever holding 50% stake each in the entity

Biocon established Syngene International Pvt. Ltd

Unilever acquired Biocon’s Irish Parent

Biocon established Syngene International Pvt. Ltd